Zolbetuximab plus mFOLFOX6 for Claudin-18.2-Positive Advanced Gastric Cancer with Multiple Bone Metastases and Disseminated Intravascular Coagulation: A Case Report
Case Reports in Oncology · 22.08.2026 · 19 (1) · 1459-1467
DOI: 10.1159/cro/abzag021 ↗Kurz gefasst
Fallbericht in der Zeitschrift Case Reports in Oncology, online erschienen am 22.08.2026. Verfasst von Taichi Tamura und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Advanced gastric cancer (AGC) complicated by bone marrow carcinomatosis (BMC) and disseminated intravascular coagulation (DIC), for which there is currently no standard treatment, has a poor prognosis. Case Presentation: We report herein a 75-year-old male patient with claudin-18.2 (CLDN18.2)-positive, HER2-negative AGC who presented with multiple bone metastases and overt DIC, which raised the index of suspicion for BMC. Although his poor performance status (PS) was attributed primarily to cancer-related pain and coagulopathy, systemic chemotherapy was started with mFOLFOX6. Early in the treatment course, acute-on-chronic subdural hematoma developed in the presence of severe thrombocytopenia, and the patient underwent burr-hole drainage after receiving intensive transfusion support. Once CLDN18.2 positivity was confirmed, zolbetuximab was added from cycle 2. The DIC parameters improved and stabilized. Hematological recovery followed, the primary lesion showed regression on imaging, and his PS improved modestly. He received seven cycles of zolbetuximab plus mFOLFOX6. However, his PS did not recover sufficiently to permit the continuation of outpatient infusional chemotherapy, prompting a treatment transition to S-1 monotherapy followed by best supportive care. The patient survived 233 days after the initial diagnosis.
Conclusion
The present case demonstrated that zolbetuximab-containing therapy combined with multidisciplinary management can be a feasible option for selected patients with CLDN18.2-positive AGC complicated by DIC and clinically suspected BMC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
- Department of Neurosurgery, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
- Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan.
Zitieren
APA
Tamura, T., Kanemasa, Y., Fujita, K., Sawabe, T., Takahara, A., Nakamura, S., Okuya, T., Yagi, Y., Kusuhara, S., Matsuda, S., Yoshioka, R., Horiguchi, S., & Shimoyama, T. (2026). Zolbetuximab plus mFOLFOX6 for Claudin-18.2-Positive Advanced Gastric Cancer with Multiple Bone Metastases and Disseminated Intravascular Coagulation: A Case Report. Case Reports in Oncology, 19(1), 1459-1467. https://doi.org/10.1159/cro/abzag021
Vancouver
Tamura T, Kanemasa Y, Fujita K, Sawabe T, Takahara A, Nakamura S, et al. Zolbetuximab plus mFOLFOX6 for Claudin-18.2-Positive Advanced Gastric Cancer with Multiple Bone Metastases and Disseminated Intravascular Coagulation: A Case Report. Case Reports in Oncology. 2026;19(1):1459-1467. doi:10.1159/cro/abzag021
BibTeX
@article{Tamura2026,
author = {Tamura, Taichi and Kanemasa, Yusuke and Fujita, Kumiko and Sawabe, Taro and Takahara, Ai and Nakamura, Shohei and Okuya, Toshihiro and Yagi, Yu and Kusuhara, Shota and Matsuda, Shinichiro and Yoshioka, Ryosuke and Horiguchi, Shin-Ichiro and Shimoyama, Tatsu},
title = {Zolbetuximab plus mFOLFOX6 for Claudin-18.2-Positive Advanced Gastric Cancer with Multiple Bone Metastases and Disseminated Intravascular Coagulation: A Case Report},
journal = {Case Reports in Oncology},
year = {2026},
volume = {19},
number = {1},
pages = {1459--1467},
doi = {10.1159/cro/abzag021}
}
EUVIMED